Please note the slight change in name for this drug and the expectation that it will be moving into Phase 3.
ATL/TV1102 reduces disease activity in multiple sclerosis patients 30 June 2008
Teva Pharmaceutical Industries Ltd. and Antisense Therapeutics Ltd. announced that anti-sense drug, ATL/TV1102, significantly reduced disease activity in patients with relapsing-remitting multiple sclerosis.
The companies noted that their Phase IIa study met its primary endpoint showing a significant reduction by 54.4% in cumulative number of new active lesions in patients taking ATL/TV1102, compared to placebo. In general, ATL/TV1102 was well tolerated.
Based on these encouraging results, Teva said it intends to conduct additional pre-clinical and clinical research before continuing to a Phase III study with ATL/TV1102.
Antisense Therapeutics has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) is in the advanced stages of a Phase IIa trial as a potential treatment of multiple sclerosis. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL/TV1102 has been licensed to Teva.
Teva is responsible for funding and performing future development activities for ATL/TV1102.
Teva's decision to move forward with the development of ATL/TV1102 will earn a US$4 million milestone payment under the license agreement between Teva and Antisense Therapeutics.
Source: RTTNews © 2008 RTTNews 30 June 2008